Novartis India Limited

September 07, 2026

To,
The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code – 500672

Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Ref: Meeting of Board of Directors of Novartis India Limited ("Company") held on September 7, 2026.

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Schedule III Part A Para B of SEBI Listing Regulations, we hereby inform that the Board of Directors ("**Board**") of the Company at its meeting held on September 7, 2026 has approved the acquisition of trademarks 'Minipress' and 'Minipres' registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA for an total aggregate consideration of INR 1250,00,10,000 (One Thousand Two Hundred Fifty Crores and Ten Thousand only) ("Transaction"). Pursuant to such approval, on September 7, 2026, the Company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. USA and Pfizer Products Inc. USA in connection with and for the purposes of the Transaction. The signing and closing of the Transaction under the asset purchase agreement is to occur simultaneously.

Further, the disclosures pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in **Annexure I**.

You are requested to take the above information on record.

Thank you.

Yours Sincerely,
For **Novartis India Limited**

CHANDNI BHUPENDRA MARU
Digitally signed by CHANDNI BHUPENDRA MARU
Date: 2026.09.07 11:18:52 +05'30'

Chandni Maru
Company Secretary and Compliance Officer
Mno. A60291

Encl.: as above

Annexure I

Details pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

S No.	Particulars	Details
1	Name(s) of parties with whom the agreement is entered	1. Novartis India Limited ("**Company**"); 2. Pfizer Inc. USA ; and 3. Pfizer Products Inc. USA
2	Purpose of entering into the agreement	Assignment of trademarks 'Minipress' and 'Minipres' registered in India and certain related intellectual property rights by Pfizer Inc. and Pfizer Products Inc. in favour of the Company ("**Assignment**").
3	Size of agreement	The total aggregate consideration payable by the Company to Pfizer Inc. USA and Pfizer Products Inc. USA for the Transaction is INR 1250,00,10,000 (One Thousand Two Hundred Fifty Crores and Ten Thousand only). As per IQVIA MAT July'26 data, Minipress XL recorded revenue of INR 228.6 crores and has been growing at a CAGR of 6.3 % for past four years while the category has been growing at 9 % CAGR for past four years. Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH).
4	Shareholding, if any, in the entity with whom the agreement is executed	Not applicable
5	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Not applicable
6	Whether the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	No, the counterparty is not related to promoter/promoter group/ group companies in any manner.
7	Whether the transaction would fall within related party	No, this is not a related party transaction.

S No.	Particulars	Details
	transactions? If yes, whether the same is done at "arm's length"	
8	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not applicable
9	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Not applicable
10	Any other disclosures related to such agreements *viz.*, details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not applicable
11	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): (i) name of parties to the agreement; (ii) nature of the agreement; (iii) date of execution of the agreement; (iv) details of amendment and impact thereof or reasons of termination and impact thereof.	Not applicable